Description (Description)
Chemical structure of gabapentin showing a cyclohexane ring with attached aminomethyl and carboxymethyl groups.*
Gabapentin Tablet, Coated
Product Images NDC 80425-0201
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 80425-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Fig 1 (Fig 1)
A line graph depicting mean pain scores over an 8-week period comparing placebo with Gabapentin at 3,600 mg/day. The x-axis represents weeks, including a 4-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 9. Gabapentin shows a decreasing pain score trend compared to placebo.*
Label 1 (Lable 1)
Gabapentin 800 mg coated tablets packaging label from Advanced Rx of Tennessee, LLC. The label includes storage instructions, a barcode, lot number, expiration date of 11/3/2023, and comparison to Neurontin with corresponding National Drug Codes (NDC). The label also identifies Westminster Pha as involved with the product.*
Label 2 (Lable 2)
Gabapentin 800 mg coated tablet label from Advanced Rx of Tennessee, LLC. The label includes storage instructions, a barcode, lot number, expiration date (11/3/2023), and references the NDC 80425-0204-02 and source NDC 69367-0347-05. It is packaged in a quantity of 60 tablets.*
Fig 2 (Fig 2)
A line graph displaying mean pain score over weeks during a 3-week dose titration period followed by a 4-week fixed dose period. The graph compares placebo, Gabapentin 1,800 mg/day, and Gabapentin 2,400 mg/day treatment groups, showing decreasing pain scores for Gabapentin groups over time.*
Fig 3 (Fig 3)
A bar chart comparing percentage outcomes in two studies. Study 1 shows 12% for placebo (PBO) and 29% for Gabapentin (GBP) 3,600 mg. Study 2 shows 14% for placebo, 32% for GBP 1,800 mg, and 34% for GBP 2,400 mg. Significance markers indicate p-values below 0.01 and 0.001.*
Fig 4 (Fig 4)
A scatter plot chart illustrating differences (%) on the y-axis against daily dose (mg) on the x-axis for Gabapentin. It compares data points from three studies labeled Study a, Study b, and Study c, each represented by different colored markers, showing varying difference percentages across doses ranging approximately from 600 mg to 1800 mg.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
